ARIZ Precision Medicine is a company focused on developing cancer treatments using a combination of biological and nanotechnologies. The company aims to stop cancer at its root cause, preventing cancer growth and metastasis.

ARIZ Precision Medicine

ARIZ Precision Medicine is pre-clinical stage company aiming to selectively target and destroy early-stage drivers of cancer, such as the deregulated PRDM genes and proteins that were previously deemed “undruggable”.  ARIZ set out to prove that cancer cells with PRDM abnormalities could be individually targeted and destroyed without harming normal cells by utilizing knowledge of the PRDM gene family, proprietary siRNA constructs and innovative drug delivery nanotechnologies to target these cancer cells. Proof of principle studies confirmed that this approach selectively killed multiple types of cancer cells (breast, colon, lung, myeloma, etc.) thus ARIZ is continuing in the development of new drug candidates for cancer by pushing these products to testing in animal models of cancer. This will give ARIZ compelling data and intellectual property to share with pharmaceutical companies and, thus, enter into strategic partnerships to take our products to the clinic and then to market. Ultimately, through these efforts, ARIZ intends to cure cancers in a way that preserves a patient’s quality of life and avoids the harmful and adverse effects of current therapies. ARIZ is located in Davis, California and benefits from the combined knowledge of a board of experts in PRDM genes, drug delivery and drug development.

Moneta Ventures

Sacramento Angels

I will be speaking at RNA Leaders USA, taking place on September 4-5, 2024. Join me to accelerate innovation and commercialisation of #RNA therapeutics and vaccines #RNALeaders https://lnkd.in/gXaKFy2C RNA Leaders

ARIZ issued a press release proudly announcing the granting of our foundational patent by the USPTO for our siRNA-based therapeutic for lung and other cancers. Many thanks to Maya Skubatch and the team at Wilson Sonsini Goodrich & Rosati

https://lnkd.in/gA8srKQn

Proud to announce that ARIZ Precision Medicine has been selected as a Backyards Award finalist in the "Breakthrough Innovation" category.  Winners will be announced during the GFX2023 conference on October 5th.  Thanks so much to Growth Factory and Stoel Rives LLP!  Join us on the 5th to hear about our progress in developing a precision-based therapeutic for lung cancer.

msh id	COM:ARIZBIO
symbol	-
name	ARIZ Precision Medicine
homepage url	https://arizbio.com
country	US
sector	Healthcare & Health Services
industry	Biotechnology
market	PRIVATE
employee count	3
crunchbase url	-
linkedin url	https://www.linkedin.com/company/arizbio
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

ARIZ

COM:ARIZBIO

ARIZ Precision Medicine

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-